GlassScriptPhysician profile
Dominick Pastore
NPI 1386607778
$1,081,606.01
in general payments reported to CMS, 2019-2025
16 companies · $454K in 2025
The $454K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87K · 2020: $82K · 2021: $100K · 2022: $117K · 2023: $127K · 2024: $115K · 2025: $454K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $453K · Royalty Or License: $242K · Food and Beverage: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $453,376.46 |
| Royalty Or License | $241,521.00 |
| Food and Beverage | $409.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pediatric Alliance LLC | $1,080,979.46 | 2019-2025 | |
| Corium, LLC | $150.32 | 2022-2024 | Azstarys |
| Greer Laboratories, INC. | $109.81 | 2025 | Oralair |
| Merck Sharp & Dohme LLC | $71.94 | 2019-2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Pfizer INC. | $36.81 | 2019-2024 | |
| Glaxosmithkline, LLC. | $35.64 | 2019-2023 | Bexsero |
| Ironshore Pharmaceuticals INC. | $33.84 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $33.04 | 2022-2023 | Flumist Quadrivalent |
| Seqirus USA INC | $28.48 | 2022-2024 | Flucelvax |
| Sanofi Pasteur INC. | $27.99 | 2019-2020 | |
| Cranial Technologies, INC | $27.22 | 2021-2022 | |
| Sobi, INC | $21.77 | 2023 | |
| Alk-Abello, INC | $18.07 | 2025 | Neffy |
| Dompe US, INC. | $16.33 | 2025 | Oxervate |
| Supernus Pharmaceuticals, INC. | $15.29 | 2023 | Qelbree |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,025,020.73 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dominick Pastore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.